Overexpression of LNCRNA 00593 regulates cisplatin resistance in non-small cell lung cancer through the p53 pathway

doi:10.3877/cma.j.issn.1674-6902.2020.06.002

Abstract

Abstract:

Objective

To investigate the mechanism of LNCRNA 00593 regulating cisplatin resistance in non-small cell lung cancer.

Methods

Quantitative real-time PCR (RT-qPCR) was used to detect the expression of LNCRNA 00593 in normal paracancer tissues (Normal), lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), HEB cell, A549 cell, H1299 cell, PC9 cell, H460 cell and calu3 cell. H1299 cells were treated with different concentrations of CDPP (0 μM, 5 μM, 10 μM), the expression of LNCRNA 00593 in cisplatin-treated cells was detected by RT-qPCR. After treating H1299 cells with CDPP for 0 h, 12 h, 24 h, 36 h, 48 h, the expression of LNCRNA 00593 in the H1299 cells was detected by RT-qPCR. The effects of overexpression and down-regulation of LNCRNA 00593 on cisplatin resistance of H1299 cells were analyzed by CCK-8 and flow cytometry. The expression of p53 in H1299 cells was detected by RT-qPCR and Western blot after overexpression and down-regulation of LNCRNA 00593, and the binding of LNCRNA 00593 and p53 was verified by RNA-pull down. The effects of LNCRNA 00593 on the viability and apoptosis of H1299 cells induced by cisplatin were detected after PFT-α treatment.

Results

The expression level of LNCRNA 00593 in non-small cell lung cancer tissues was significantly lower than that in adjacent normal tissues (P<0.05). The expression levels of LNCRNA 00593 in A549, H1299, PC9, H460 and calu3 cells were significantly lower than that of HEB cells (P<0.01). After treating H1299 cells with 0 μM, 5 μM, and 10 μM CDPP respectively, the expression of LNCRNA 00593 increased in a concentration-dependent manner (P<0.01). After treating H1299 cells with 10 μM CDPP for 12 h, 24 h, 36 h, 48 h, the expression of LNCRNA 00593 increased in a time-dependent manner (P<0.01). After CDPP treatment, down-regulation of LNCRNA 00593 significantly increased H1299 cell activity and decreased apoptosis rate, while overexpression of LNCRNA 00593 significantly decreased H1299 cell activity and increased apoptosis rate. Overexpression of LNCRNA 00593 activated the p53 pathway, and LNCRNA 00593 can bind to p53. The regulation of cisplatin resistance of H1299 cells by LNCRNA 00593 was down-regulated in PFT-α-treated cells.

Conclusion

Overexpression of LNCRNA 00593 regulates cisplatin resistance in non-small cell lung cancer cells through the p53 pathway.

Key words: LNCRNA 00593, p53 pathway, Non-small cell lung cancer, Cisplatin resistance

Zheng Li, Meng Zhao, Peng Ge, Aimin Zhang, Li Ren. Overexpression of LNCRNA 00593 regulates cisplatin resistance in non-small cell lung cancer through the p53 pathway[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(06): 724-730.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.06.002

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I06/724

Figures/Tables 5

References 32

1	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2	任成山，钱桂生. 支气管肺癌研究的新思维[J/CD]. 中华肺部疾病杂志(电子版), 2009, 2(3): 143-146.
3	中华医学会，中华医学会肿瘤学分会，中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版)[J]. 肿瘤研究与临床，2018, 30(12): 793-824.
4	任晓跃，赵　红，冯谢敏，等. 国内外恶性肿瘤发病率及死亡率数据分析[J]. 医药前沿，2018, 8(9): 376-377.
5	Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer[J]. Lancet Oncol, 2015，16: e447-e459.
6	陈万青，张思维，邹小农. 中国肺癌发病死亡的估计和流行趋势研究[J]. 中国肺癌杂志，2010, 13(5): 488-493.
7	Yarmishyn AA, Kurochkin IV. Long noncoding RNAs: A potential novel class of cancer biomarkers[J]. Front Genet, 2015, 6: 145.
8	付志雪，梁　军. 局部晚期H1299放疗联合分子靶向治疗的研究进展[J]. 中华放射肿瘤学杂志，2016, 25(12): 1369-1374.
9	Ahmadi S, Zobeiri M, Bradburn S. Molecular mechanisms underlying actions of certain long noncoding RNAs in Alzheimer′s disease[J]. Metabolic Brain Disease, 2020, 35(5): 681-693.
10	Li H, Ma SQ, Huang J, et al. Roles of long noncoding RNAs in colorectal cancer metastasis[J]. Oncotarget, 2017, 8(24): 39859-39876.
11	Liu KS, Li TP, Ton H, et al. Advances of long noncoding RNAs-mediated regulation in reproduction[J]. Chinese Med J, 2018, 131(2): 226-234.
12	Wang Y, Duan Y, Li WX, et al. Integrated analysis of lncRNAs and mRNAs identifies a potential driver lncRNA FENDRR in lung cancer in Xuanwei, China[J]. Nutrit Cancer, 2020, (3): 1-13.
13	Liu X, Zhao Y, Li Y, et al. Quantitative assessment of lncRNA H19 polymorphisms and cancer risk: a meta-analysis based on 48，166 subjects[J]. Artificial Cells, 2020, 48(1): 15-27.
14	Liu Z, Sun M, Lu K, et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21WAF1/CIP1 expression[J]. PLoS ONE, 2013，DOI: 10.1371/journal.pone.0077293.
15	Sun J, Pan LM, Chen LB, et al. LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis[J]. Cell Cycle, 2017: 1-8.
16	Gong W, Cao Y, Wang Y, et al. Upregulation of LncRNA FEZF-AS1 is associated with advanced clinical stages and family history of cancer in patients with H1299[J]. Pathology Research & Practice, 2018, 214(6): 857-861.
17	Qi F, Yan Q, Zheng Z. Geraniol and geranyl acetate induce potent anticancer effects in colon cancer Colo-205 cells by inducing apoptosis, DNA damage and cell cycle arrest[J]. J Buon, 2018, 23(2): 346-352.
18	潘有光，傅文凡，莫益俊，等. MiR-92b-3p通过靶向RAD21增强非小细胞肺癌对顺铂的化学敏感性[J]. 实用医学杂志，2020, 11(14): 1897-1902.
19	郭　浩，周淑妮，冉瑞智. 吉非替尼联合培美曲塞和顺铂治疗晚期非小细胞肺癌的安全性和有效性[J]. 现代肿瘤医学，2019, 27(5): 796-800.
20	柳　丹，武福云，李　珊，等. 多药耐药基因MDR1和细胞自噬在肿瘤多重耐药机制中的研究进展[J]. 中国现代医学杂志，2018, 28(24): 38-42.
21	张　艳，刘　晶，杨梦迪. 非小细胞肺癌晚期靶向药物治疗中血清肿瘤标志物预测疗效的临床意义[J]. 临床药物治疗杂志，2014, 12(5): 35-39.
22	刘　露. 非小细胞肺癌晚期靶向药物治疗中血清肿瘤标志物预测疗效的临床意义[J]. 牡丹江医学院学报，2016, 23(5): 97-99.
23	Hu X, Bao J, Wang Z, et al. The plasma lncRNA acting as fingerprint in non-small-cell lung cancer[J]. Tumor Biology, 2016, 37(3): 3497-3504.
24	Yun C, Fuming Z, Chunkai Z, et al. Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway[J]. Oncotarget, 2017, 8(11): 17785-17794.
25	Wang L, Shang X, Feng Q. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis[J]. Cancer Biology & Therapy, 2018, 20(3): 1-11.
26	Ge P, Cao L, Yao YJ, et al. lncRNA FOXD2-AS1 confers cisplatin resistance of non-small-cell lung cancer via regulation of miR185-5p-SIX1 axis[J]. OncoTargets Therapy, 2019, 12: 6105-6117.
27	Kang R, Kroemer G, Tang D. The tumor suppressor protein p53 and the ferroptosis network[J]. Free Radical Biol Med, 2018: S0891584918309079.
28	荣璐璐，薛丽燕，薛学敏，等. 食管梭形细胞癌p53蛋白的表达与临床病理特征及预后分析[J]. 中华病理学杂志，2020, 49(7): 715-720.
29	Zhou MJ, Chen FZ, Chen HC, et al. ISG15 inhibits cancer cell growth and promotes apoptosis[J]. Int J Mol Med, 2017, 39: 446-452.
30	He S, Ma X, Ye Y, et al. HEATR1 modulates cell survival in non-small cell lung cancer via activation of the p53/PUMA signaling pathway[J]. OncoTargets Therapy, 2019, 12: 4001-4011.
31	Quintanal-Villalonga L, Mediano Mariló, Ferrer I, et al. Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer[J]. Oncotarget, 2018, 9(28): 19945-19960.
32	Ying X, Yuechao L, Tianbo L, et al. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway[J]. Cell Communicat Signaling, 2018, 16(1): 43-58.

[1]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[2]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[3]	Yuan Wang, Yi Yang, Yunfei Mou, Fuqiang Ren, Xin Huang. Analysis of postoperative osimertinib targeted therapy in patients with resectable non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(05): 657-660.
[4]	Ling Ma, Yinglong Li, Na Yue, Lifei Yang. Expression and clinical value of differential proteins in exosomes from non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(03): 327-330.
[5]	Xiaoqin Weng, Jiayang Qin, Yang Zhang, Jin Cui, Hong Shen. Effect of HIF-1α/VEGF-VEGFR2/Nrp-1 on Treg proliferation in NSCLC patients [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(06): 717-722.
[6]	Zhiguo Yu, Bo Gong, Weihua Lu, Minfang Li. Silencing HIF-1α regulates MAPK/ERK pathway and inhibits metastasis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 573-578.
[7]	Rui Xu, Yong Qian, Haiyan Zhang. Study on the mechanism of miR-515-5p enhanced the cisplatin sensitivity of NSCLC A549/DDP cells via targeting RING1 [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 559-563.
[8]	Tiantian Wang, Yuan Wen, Zhen Li, Meihong Ye, Ying Guo, Shuang Ma. The effect of honokiol on the sensitivity of gastric cancer cells to cisplatin chemotherapy by regulating the Nrf2/ARE pathway [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 202-209.
[9]	Jiu Yang, Mei Hong, Zhiyuan Liu, Nuo Zhu. Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 948-953.
[10]	Bo Zhang, Bo Jin. Progress in research of Met as a target in non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 797-800.
[11]	Jingxiu Niu, Lihong Zhang, Hui Wang. Clinical study on the improvement of adverse reactions related to paclitaxel combined with cisplatin chemotherapy in advanced non-small cell lung cancer by grey screening method [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 774-778.
[12]	Kexin Tang, Xi Lin, Hong Shan. Doxorubicin-loaded fluorescent carbon dots with PEI passivation inhibited proliferation, migration and invasion of non-small cell lung cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(02): 131-136.
[13]	Leilei Shen, Yang Liu. The staging evolution and treatment strategies of stage ⅠB non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(04): 246-254.
[14]	Xiao Liang, Lei Wang, Tao Jiang. Progress in surgical treatment of non-small cell lung cancer invading the chest wall [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 157-163.
[15]	Jianqiao Cai, Jing Huang, Lei Jiang. Double sleeve uniportal video-assisted thoracoscopic lobectomy—a retrospective study from shanghai pulmonary hospital [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 144-149.

Please choose a citation manager

Content to export